Results 81 to 90 of about 3,613 (152)

Development of an experimental method using Cs-131 to evaluate radiobiological effects of internalized Auger-electron emitters. [PDF]

, 2016
Fredericia, Pil, Groesser, Torsten, Jensen, Mikael, Köster, Ulli, Severin, Gregory   +4 more
core  

Renal function affects absorbed dose to the kidneys and haematological toxicity during Lu-DOTATATE treatment [PDF]

core   +1 more source

In Vivo Studies of [¹⁶¹Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2-Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth Suppression. [PDF]

J Nucl Med
Cold S, Sadasivam P, Wessel MM, Ischyropoulou M, Fonslet J, Engel TB, Nielsen CH, Kjaer A, Kristensen LK.   +8 more
europepmc   +1 more source

Occupational radiation safety and sustainable workforce management in PET/CT practice: a pilot study of healthcare professionals in a newly established cyclotron-based nuclear medicine center. [PDF]

Front Public Health
Marshall SK, Mewes K, Noomad N, Durawee W, Hayeeabdunromae A.   +4 more
europepmc   +1 more source

Recent trends in the utilization of molecular breast imaging in the United States. [PDF]

Clin Imaging
Dave R, Gu L, Garrett HV, Bennett D, Stwalley D, Singer S, Chiu S, Lee MV.   +7 more
europepmc   +1 more source

Strategic Objectives of Nanotechnology-Driven Repurposing in Radiopharmacy-Implications for Radiopharmaceutical Repurposing (Beyond Oncology). [PDF]

Pharmaceutics
Salgueiro MJ, Zubillaga M.
europepmc   +1 more source

Opportunities for Improving the Drug Development Process: Results from a Survey of Industry and the FDA [PDF]

In the United States, the Food and Drug Administration (FDA) agency is responsible for regulating the safety and efficacy of biopharmaceutical drug products. Furthermore, the FDA is tasked with speeding new medical innovations to market.
Adrian H. B. Gottschalk, Ernst R. Berndt, Matthew W. Strobeck   +2 more
core  

Fluorination augments tumor engagement and antitumor immunity of a D-peptide-based radiotheranostic agent for combinatorial immune checkpoint blockade therapy. [PDF]

J Immunother Cancer
Zhang S, Liu C, Lu Q, Liu W, Wu J, Liu J, Tong L, Zhao K, Hu Q, Chen X, Li L, Song X, Wang F, Dai D, Wang R, Hu K.   +15 more
europepmc   +1 more source

Evaluation of coadministration schedules of rA1M for kidney protection after administration of 177Lu-octreotide. [PDF]

Radiat Prot Dosimetry
Rassol N, Ytterbrink C, Pettersson D, Al-Awar A, Bakr H, Gram M, Spetz J, Forssell-Aronsson E.   +7 more
europepmc   +1 more source

International Evaluation of Research and Doctoral Training at the University of Helsinki 2005-2010 : RC-Specific Evaluation of HYRL - Laboratory of Radiochemistry [PDF]

, 2012

core